Castellum, Inc. Announces Intent to Uplist to NYSE American Exchange

By Dr. Matthew Watson

POTOMAC, Md., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Castellum, Inc. (“Castellum”) (OTC: ONOV), a cybersecurity, electronic warfare, and IT services company, announced today that, subject to meeting all requirements (including the price requirement) at the time of listing, the Company’s application to list its shares of common stock (the “Common Stock”), has been approved to uplist to the NYSE American Exchange in conjunction with an underwritten public offering and a one-for-twenty reverse stock split of the Common Stock effective on or about October 7, 2022. The ticker symbol for the Common Stock will change to “CTM” upon listing. Trading of the Common Stock is expected to commence on or about October 7, 2022. The new CUSIP for the Common Stock following the reverse stock split will be 14838T204.

Read the rest here:
Castellum, Inc. Announces Intent to Uplist to NYSE American Exchange

Related Post


categoriaGlobal News Feed commentoComments Off on Castellum, Inc. Announces Intent to Uplist to NYSE American Exchange | dataOctober 5th, 2022

About...

This author published 5532 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024